LBT Innovations (ASX:LBT) share price plummets 14% despite positive update

The company's shares are off to a bad start this week…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The LBT Innovations Limited (ASX: LBT) share price is deep in the red today. This comes regardless of the medical technology company providing investors with a positive update yesterday.

At the time of writing, LBT Innovations shares are down a sizeable 14.29% to 12 cents apiece.

doctor looks out window resting head in hand

Image source: Getty Images

What did LBT Innovations announce?

According to its announcement, LBT Innovations advised Clever Culture Systems (CCS) has signed an exclusive distribution agreement with Thermo Fisher Scientific.

CCS is a joint-venture company owned equally by LBT Innovations and German medical equipment group Hettich.

Thermo Fisher is a leading provider of instrumentation and consumables in the US microbiology market.

The 5-year deal will see Thermo Fisher become the exclusive distributor for the company's automated culture plate reader, APAS Independence, in the US.

APAS Independence is the first and only FDA-cleared automated culture plate reader available in the United States. The innovative technology uses advanced imaging and artificial intelligence to interpret bacterial growth on culture plates.

Under the agreement, Thermo Fisher will engage in sales and marketing activities for APAS Independence in the US. In addition, the company will also provide installation, maintenance and support services to customers.

The agreement is a major milestone for LBT Innovations as it will provide sales and commercial activities in the US market which is the largest in the world. It offers more than 1,500 target laboratories for the potential placement of APAS Independence readers.

LBT Innovations CEO and managing director Brent Barnes commented:

This is a really important milestone for LBT and represents a major step forward in our commercialisation strategy in the United States.

We have spoken previously about the importance of appointing well recognised, leading distributors to support our sales efforts in key markets. Thermo Fisher is a leader in microbiology that is recognised globally, and we will benefit greatly from the depth and strength of their sales team in the United States…

We are very pleased to now have two of the world's largest microbiology companies selling our technology across the two main markets of the United States and Europe, which is a further validation of benefits of our technology.

LBT Innovations share price summary

Since the beginning of the year, LBT Innovations shares have moved in circles, remaining relatively unchanged for the period. When zooming out to the last 12 months, however, its shares are down around 8%.

LBT Innovations presides a market capitalisation of roughly $33 million and has over 289 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »